Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
1.200
-0.020 (-1.64%)
At close: Sep 8, 2026, 4:00 PM EDT
1.163
-0.057 (-4.66%)
After-hours: Sep 8, 2026, 7:59 PM EDT
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$2,308,760
Market Cap
4.28M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
| Sep 30, 2022 | 1 | - | - |
| Jun 30, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| VivoSim Labs | 15 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Galmed Pharmaceuticals | 6 |
| Mustang Bio | 4 |
| Addex Therapeutics | 3 |
| Silo Pharma | 3 |
CVKD News
- 5 days ago - Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - GlobeNewsWire
- 8 days ago - Cadrenal Therapeutics gets feedback from CAD-1005 Type D Meeting with FDA - TheFly
- 8 days ago - Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia - GlobeNewsWire
- 26 days ago - Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process - GlobeNewsWire
- 26 days ago - Cadrenal Therapeutics Quarterly report: Q2 2026 - Filings
- 26 days ago - Cadrenal Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation - GlobeNewsWire
- 5 weeks ago - Cadrenal Therapeutics Proxy statement: Proxy filing - Filings